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1  | INTRODUC TION
Chronic	 hepatitis	 B	 or	 C	 virus	 (HBV/HCV)	 infection	 is	 associated	
with	the	development	of	liver	cirrhosis	and	hepatocellular	carcinoma	
(HCC).	In	human	immunodeficiency	virus	(HIV)	co‐infected	patients,	
the	risk	for	 liver	decompensation,	 liver‐related	death	and	develop‐
ment	of	HCC	is	increased.1
The	 incidence	 of	HCC	 is	 rising	 in	HIV/HCV	 co‐infected	 indi‐
viduals.1	 When	 ultrasonographic	 screening	 is	 performed	 every	
6	months,	HCC	may	be	diagnosed	in	an	earlier	stage	allowing	cu‐
rative	treatment.	Therefore,	 it	 is	 recommended	 in	multiple	 inter‐
national	guidelines	(AASLD,	EASL	and	EACS)	to	screen	individuals	
with	 cirrhosis	 twice	 a	 year	 with	 ultrasound	 for	 the	 presence	 of	
HCC.
Although	 an	 earlier	 survey	 showed	 that	 awareness	 of	 HCC	
screening	guidelines	in	selected	HIV	treatment	centres	in	the	United	
States	is	high,2	adherence	to	bi‐annual	HCC	screening	guidelines	in	
viral	hepatitis	patients	is	low,	varying	from	13%	to	51%.3‐7
Our	aim	was	to	assess	compliance	with	HCC	screening	guidelines	
in	a	large	European	cohort	of	HIV‐infected	patients	with	HBV	and/or	
HCV	co‐infection	and	cirrhosis.
2  | PATIENTS AND METHODS
2.1 | Study population
Individuals	 included	 in	 this	 study	 were	 enrolled	 in	 observational	
HIV	cohorts	participating	in	the	Collaboration	of	Observational	HIV	
Epidemiological	 Research	 in	 Europe	 (COHERE).	 COHERE	 is	 a	 col‐
laboration	of	40	cohorts	across	Europe	and	is	part	of	the	EuroCoord	
network.8	Our	analyses	were	based	on	data	pooled	in	the	COHERE	
in	EuroCoord	merger	in	July	2015.
HBV	and/or	HCV	co‐infected	HIV	patients	aged	above	18	years	
at	the	time	of	HIV	diagnosis	were	included.	Only	data	from	cohorts	
who	 routinely	 document	 ultrasound	 results	 were	 collected.	 Four	
cohorts	 from	 Austria	 (Austrian	 HIV	 Cohort	 Study	 [AHIVCOS]),	
the	 Netherlands	 (AIDS	 Therapy	 Evaluation	 in	 the	 Netherlands	
[ATHENA]),	France	(French	national	prospective	cohort	of	patients	
co‐infected	with	HIV	 and	HCV	 [ANRS	CO13	HEPAVIH])	 and	 Italy	
(Hospital	San	Raffaele)	provided	data	for	our	analysis.
Patients	 were	 followed	 up	 starting	 1	 January	 2005	 until	 1	
January	2015.	HBV	co‐infection	was	defined	as	being	HBsAg‐pos‐
itive	and	HCV	co‐infection	as	HCV	antibody‐positive.	Assessment	
of	 liver	 cirrhosis	was	 based	on	 clinical	 diagnosis	 reported	 in	 the	
chart,	 liver	biopsy	or	Fibroscan	 result	 (≥18.1	 kPa	 for	HBV	 infec‐
tion9	 and	 ≥12.6	 kPa	 for	HCV	 infection10).	 The	 observation	 time	
started	on	the	date	of	liver	cirrhosis	and	continued	until	the	earli‐
est	of	the	following:	death,	lost	to	follow‐up,	cohort	censoring	date	
or	1	January	2015.	Compliance	with	HCC	screening	guidelines	was	
defined	 as	 at	 least	 one	 ultrasound	 every	 6	months	 after	 the	 di‐
agnosis	of	 cirrhosis,	with	a	 two‐week	grace	period	 (6.5	months).	
Observation	time	started	from	the	date	of	cirrhosis	diagnosis	and	
continued	 until	 the	 first	 ultrasound	 and	 “re‐started”	 after	 each	
ultrasound.	Patients	were	censored	at	the	end	of	their	 last	com‐
plete	 observation	 period	 of	 6.5	months;	 in	 case,	 the	 last	 obser‐
vation	period	was	<6.5	months	because	of	the	database	closure,	
death	 or	 lost	 to	 follow‐up.	 Compliance	 was	 included	 as	 a	 time‐
varying	 outcome,	 and	 therefore,	 patients	 could	 switch	 between	
the	 compliance	and	noncompliance	groups.	Additionally,	 compli‐
ance	with	HCC	 screening	 guidelines	was	 assessed	 in	 relation	 to	
frequency	 of	 outpatient	 visits	 and	HIV‐RNA	measurements	 as	 a	
proxy	for	being	linked	to	care	(number	of	visits	and	HIV‐RNA	mea‐
surements	per	full	year	of	follow‐up,	categorized	as	≥2	or	<2/year).
Validation	of	ultrasound	data	was	performed	by	manually	check‐
ing	random	samples	of	10%	of	all	data	from	each	cohort;	the	data	
from	the	ATHENA	cohort	were	manually	checked	in	>75%.
2.2 | Statistical analysis
Predictors	for	low	compliance	were	analysed	within	a	logistic	regres‐
sion	model	using	the	generalized	estimating	equation	(GEE)	method	
with	a	logit	link	function	and	an	exchangeable	correlation	structure	
to	adjust	for	correlations	between	ultrasounds	within	the	same	in‐
dividuals.	Univariate	GEE	analyses	were	used	to	determine	factors	
associated	with	compliance	rate.	Because	age	at	baseline	in	our	GEE	
model	does	not	accurately	reflect	the	effect	of	age	on	the	odds	of	
being	 screened,	we	used	 ‘time‐updated’	 age,	 increasing	 the	age	 in	
accordance	with	the	increase	in	follow‐up	time.
All	 variables	with	 a	P‐value	 <0.2	were	 considered	 as	 potential	
independent	 determinants	 and	 were	 included	 in	 the	 multivariate	
model.	A	P‐value	<0.05	was	considered	statistically	significant.	All	
analyses	 were	 performed	 using	 SAS	 v9.4.	 Additional	 sensitivity	
analyses	were	conducted,	in	which	the	allowed	time	to	comply	with	
HCC	screening	guidelines	between	ultrasound	measurements	was	
extended	to	9	and	12	months,	and	the	Fibroscan	score	for	the	diag‐
nosis	of	cirrhosis	in	HCV	patients	was	set	to	≥14.6	kPa.	Additionally,	
the	 effect	 of	 these	 analyses	 on	 outcome	was	 assessed,	 using	 the	
multivariate	GEE	analyses.
3  | RESULTS
Data	 from	6431	HBV	and	HCV	co‐infected	HIV	patients	were	 in‐
cluded.	Of	these	patients,	1183	fulfilled	the	criteria	of	liver	cirrhosis	
according	to	their	clinical	chart,	liver	biopsy	or	Fibroscan,	of	whom	
537	were	excluded	due	to	lack	of	follow‐up	after	the	date	of	cirrhosis	
assessment,	resulting	in	646	individuals	who	were	selected	for	anal‐
ysis	(Table	1).	Of	these	patients,	518	(80%)	were	HCV	co‐infected,	
85	(13%)	HBV	co‐infected	and	43	(7%)	HCV	and	HBV	co‐infected.
The	 proportion	 of	 patients	 in	 whom	 HCC	 screening	 was	 per‐
formed	 according	 to	 screening	 guidelines	 varied	 between	5.4%	 in	
2005,	18.4%	in	2008	and	14.2%	in	2014	(Figure	1).
Results	from	the	univariate	model	showed	that	older	age	than	
40	years	(40‐50	years:	OR	2.02;	95%	CI	1.45‐2.80,	≥50	years:	OR	
2.59;	 95%	 CI	 1.80‐3.70),	 being	 HIV	 infected	 by	 IDU	 compared	
with	MSM	(OR	3.16;	95%	CI	2.18‐4.48),	 longer	duration	of	cART	
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use	 (OR	1.44;	95%	CI	1.30‐1.60	per	5‐year	 increase)	 and	 longer	
duration	since	cirrhosis	diagnosis	(OR	1.65;	95%	CI	1.21‐1.52	per	
5‐year	increase)	were	all	associated	with	being	screened	for	HCC	
<6.5	months.	Cirrhosis	diagnosis	based	on	liver	biopsy	or	Fibroscan	
was	also	associated	with	higher	compliance	compared	with	diag‐
nosis	based	on	clinical	events	only	(OR	1.82;	95%	CI	1.28‐2.56).	In	
patients	with	HBV‐HIV	co‐infection,	 the	odds	of	being	screened	
were	lower	(OR	0.44;	95%	CI	0.31‐0.65)	compared	to	those	with	
HCV‐HIV	 co‐infection.	 In	 the	 multivariate	 analysis,	 longer	 fol‐
low‐up	after	cirrhosis	diagnosis	 (OR	1.59;	95%	CI	1.36‐1.87)	and	
cirrhosis	 diagnosis	 based	 on	 liver	 biopsy	 or	 Fibroscan	 (OR	1.68;	
1.11‐2.55)	remained	independently	associated	with	a	higher	com‐
pliance.	 Lack	 of	ALT	measurements	 (OR	0.52;	 95%	CI	 0.31‐0.86	
compared	 with	 normal	 ALT	 levels)	 was	 associated	 with	 a	 lower	
compliance.	More	recent	calendar	year	of	follow‐up,	included	as	a	
time‐updated	variable	to	the	model,	was	not	significantly	associ‐
ated	with	better	compliance.
Of	 the	 patients	 with	 ≥2	 clinic	 visits	 per	 year,	 18%	 had	 HCC	
screening	<6.5	months,	compared	to	3%	among	those	with	<2	clinic	
visits	per	year.	Of	the	patients	with	≥2	HIV‐RNA	measurements	per	
year,	16%	had	HCC	screening	<6.5	months,	compared	to	12%	among	
those	with	<2	HIV‐RNA	measurements	per	year.
Validation	of	the	ultrasound	data	showed	that	for	two	cohorts’	
ultrasound	 data	 had	 been	missed.	 In	 the	 random	 sample	 of	 these	
two	cohorts,	the	missed	ultrasound	data	had	led	to	underreporting	
of	HCC	screening	<6.5	months	of	10%	and	15%,	respectively.	When	
the	analyses	were	repeated	only	for	the	cohorts	with	complete	data,	
the	 rate	 of	 compliance	 did	 not	 change,	 and	 the	 results	 from	GEE	
analyses	 showed	 the	 same	associations	 as	when	data	 from	all	 co‐
horts	were	included.
Sensitivity	 analyses	 in	 which	 the	 screening	 intervals	 between	
ultrasounds	were	 increased	to	9	and	12	months	showed	a	varying	
compliance	 of	 7%	 (2005),	 12%	 (2006),	 17%‐18%	 (2007,	 2011)	 to	
20%‐24%	(2008‐2010	and	2012‐2014)	for	9‐month	intervals,	and	of	
7%	 (2005),	 14%	 (2006),	 20%	 (2007)	 to	 26%‐30%	 (2008‐2014)	 for	
12‐month	intervals.
Multivariate	 analysis	 performed	 after	 extending	 the	 permitted	
time	between	ultrasounds	 to	 9	months	 showed	 comparable	 asso‐
ciations	 to	 those	 found	with	 the	 6.5‐month	 interval.	 Additionally,	
longer	duration	of	cART	use	was	now	associated	with	a	higher	com‐
pliance	(per	5‐year	increase	OR	1.19;	95%	CI	1.05‐1.34).
4  | DISCUSSION
We	observed	a	strikingly	low	adherence	of	5%‐18%	to	HCC	screen‐
ing	guidelines	 in	a	prospective	European	cohort	of	HIV/HBV,	HIV/
HCV	 and	 HIV/HCV/HBV	 co‐infected	 patients	 with	 liver	 cirrhosis.	
Although	 low	adherence	 to	bi‐annual	HCC	screening	guidelines	of	
13%‐51%	has	been	reported	previously	in	HBV	and	HCV	mono‐in‐
fected	patients,2‐5	and	of	24%‐36%	in	HIV/HBV	or	HCV	co‐infected	
patients,6,7	the	compliance	we	report	in	HIV	co‐infected	patients	is	
even	lower.	Even	though	compliance	with	HCC	screening	guidelines	
increased	slightly	if	the	permitted	time	between	ultrasounds	was	ex‐
tended	in	our	study,	compliance	rates	remained	very	low	at	a	maxi‐
mum	of	30%	with	an	interval	of	12	months	between	ultrasounds.
Multiple	factors	are	likely	to	contribute	to	the	low	adherence	
to	HCC	screening	guidelines	in	patients	with	cirrhosis.	For	exam‐
ple,	healthcare	providers	may	have	insufficient	knowledge	about	
practice	guidelines,	and	a	standardized	system	for	scheduling	and	
TA B L E  1  Demographic	characteristics
Total N 646
Cohort AHIVCOS 115	(18%)
ATHENA 243	(38%)
HEPAVIH 242	(37%)
Hospital	San	Raffaele 46	(7%)
Age	at	cirrhosis	
diagnosis
Years	(median,	IQR) 44	(40‐49)
Gender Male 514	(80%)
Female 132	(20%)
Region	of	origin Western 537	(83%)
Sub	Saharan	Africa 34	(5%)
Other 75	(12%)
Transmission	route	
of	HIV
IDU 371	(57%)
MSM 137	(21%)
Heterosexual 75	(12%)
Other 40	(6%)
Unknown 23	(4%)
Hepatitis	co‐infection HCV 518	(80%)
HBV 85	(13%)
HCV	&	HBV 43	(7%)
Use	of	cART N 603	(93%)
Follow‐up	time	since	
diagnosis	of	cirrhosis	
(y)
Median	(IQR) 5.33	
(3.37‐9.51)
Cirrhosis	diagnosis Fibroscan 368	(57%)
Liver	biopsy 15	(2%)
Liver	biopsy	&	
Fibroscan
12	(2%)
Clinical	chart	onlya 251	(39%)
Mortality Overall 138	(21%)
Liver‐related 76	(55%)
HCC 9
Decompensated	
cirrhosis
33
HCV/HBV‐related,	NOS 34
Abbreviations:	cART,	combination	antiretroviral	therapy;	HBV,	hepatitis	
B	virus;	HCV,	hepatitis	C	virus;	HIV,	human	immunodeficiency	virus;	
IDU,	injecting	drug	use;	MSM,	men	who	have	sex	with	men;	NOS,	not	
otherwise	specified.
aClinical	diagnosis	based	on	clinical	signs	of	cirrhosis	such	as	ascites,	
hepatic	encephalopathy,	biochemical	abnormalities	(bilirubin,	albu‐
min,	INR),	signs	of	portal	hypertension	in	the	absence	of	portal	vein	
thrombosis.	
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following	 screening	 examinations	 geared	 towards	 HBV	 and/or	
HCV	care	may	be	missing,7	leading	to	patients	being	lost	to	follow‐
up.	 The	 frequency	 of	 clinic	 visits	 has	 been	 positively	 correlated	
with	adherence	to	HCC	screening	guidelines	 in	earlier	studies.4,5 
Our	study	seems	 to	confirm	this,	as	we	 found	 that	 frequency	of	
clinical	visits,	ALT	and	HIV‐RNA	measurements,	 is	positively	cor‐
related	 with	 better,	 but	 still	 low,	 compliance.	 Our	 finding	 that	
time	since	diagnosis	of	cirrhosis	was	associated	with	higher	HCC	
screening	rates	could	reflect	a	stable	surveillance	situation	where	
both	patient	and	healthcare	provider	are	aware	of	the	importance	
of	regular	follow‐up	and	are	attentive	to	the	risks	of	concomitant	
co‐morbidity.
In	 conclusion,	 our	 study	 in	 a	 prospective	 European	 cohort	 of	
HBV	and/or	HCV	co‐infected	HIV	patients	with	cirrhosis	showed	a	
very	low	rate	of	compliance	to	bi‐annual	HCC	screening	guidelines	
of	only	14%‐18%.	In	the	context	of	an	increasing	incidence	of	HCC	
among	ageing	people	living	with	HIV,1	this	finding	warrants	urgent	
action	to	ensure	better	implementation	of	HCC	screening	guidelines	
in	this	population.
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